Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology
Sandrine Belouzard
Arnaud Machelart
Valentin Sencio
Thibaut Vausselin
Eik Hoffmann
Nathalie Deboosere
Yves Rouillé
Lowiese Desmarets
Karin Séron
Adeline Danneels
Cyril Robil
Loïc Belloy
Camille Moreau
Catherine Piveteau
Alexandre Biela
Alexandre Vandeputte
Séverine Heumel
Lucie Deruyter
Julie Dumont
Florence Leroux
Ilka Engelmann
Enagnon Kazali Alidjinou
Didier Hober
Priscille Brodin
Terence Beghyn
François Trottein
Benoît Déprez
Jean Dubuisson
Arnaud Machelart
Machelart Arnaud
ORCID: 0000-0002-4444-0011
Identification of immune effectors essential to the control of primary and secondary intranasal infection with brucella melitensis in mice
10.4049/jimmunol.1502265
In situ characterization of splenic brucella melitensis reservoir cells during the chronic phase of infection in susceptible mice
10.1371/journal.pone.0137835
Brucella melitensis invades murine erythrocytes during infection.
10.1128/iai.01779-14
In situ microscopy analysis reveals local innate immune response developed around Brucella infected cells in resistant and susceptible mice
10.1371/journal.ppat.1002575
Host-directed therapies offer novel opportunities for the fight against tuberculosis
10.1016/j.drudis.2017.05.005
Erythritol availability in bovine, murine and human models highlights a potential role for the host aldose reductase during Brucella infection
10.3389/fmicb.2017.01088
Combination therapy for tuberculosis treatment: Pulmonary administration of ethionamide and booster co-loaded nanoparticles
10.1038/s41598-017-05453-3
Chronic Brucella infection induces selective and persistent IFN-γ-dependent alterations of marginal zone macrophages in the spleen.
10.1128/iai.00115-17
Proteomics of Mycobacterium infection: Moving towards a better understanding of pathogen-driven immunomodulation
10.3389/fimmu.2018.00086
Publisher Correction: Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles.
10.1038/s41598-018-25177-2
Allergic asthma favors Brucella growth in the lungs of infected mice
10.3389/fimmu.2018.01856
Intrinsic antibacterial activity of nanoparticles made of β-cyclodextrins potentiates their effect as drug nanocarriers against tuberculosis
10.1021/acsnano.8b07902
A novel codrug made of the combination of ethionamide and its potentiating booster: synthesis, self-assembly into nanoparticles and antimycobacterial evaluation
10.1039/C9OB00680J
Route of Infection Strongly Impacts the Host-Pathogen Relationship
10.3389/fimmu.2019.01589
IRG1 controls immunometabolic host response and restricts intracellular Mycobacterium tuberculosis infection
10.1101/761551
Occurrence and repair of alkylating stress in the intracellular pathogen Brucella abortus
10.1038/s41467-019-12516-8
Fragment-based optimized EthR inhibitors with in vivo ethionamide boosting activity
10.1021/acsinfecdis.9b00277
Convergent evolution of zoonoticBrucellaspecies toward the selective use of the pentose phosphate pathway
10.1073/pnas.2008939117
Paradoxical Roles of the MAL/Tirap Adaptor in Pathologies
10.3389/fimmu.2020.569127
SARS-CoV-2 infection in nonhuman primates alters the composition and functional activity of the gut microbiota
10.1080/19490976.2021.1893113
Trypanosoma infection favors Brucella elimination via IL-12/IFNγ-dependent pathways
10.3389/fimmu.2017.00903
Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology
10.1101/2021.06.30.450483
High-Content Analysis Monitoring Intracellular Trafficking and Replication of Mycobacterium tuberculosis Inside Host Cells
10.1007/978-1-0716-1460-0_29
Sandrine Belouzard
Belouzard Sandrine
ORCID: 0000-0002-9972-4054
Identification of a new benzimidazole derivative as an antiviral against hepatitis C virus
10.1128/JVI.00404-16
Identification of class II ADP-ribosylation factors as cellular factors required for hepatitis C virus replication
10.1111/cmi.12572
Middle East respiratory syndrome coronavirus infection is inhibited by griffithsin
10.1016/j.antiviral.2016.07.011
Characterization of Hepatitis C Virus Interaction with Heparan Sulfate Proteoglycans
10.1128/JVI.03647-14
Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro
10.1371/journal.pone.0142539
New Insights into the Understanding of Hepatitis C Virus Entry and Cell-to-Cell Transmission by Using the Ionophore Monensin A
10.1128/JVI.00192-15
Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action
10.1128/JVI.01473-15
Regulation of core expression during the hepatitis C virus life cycle
10.1099/vir.0.070433-0
Successful Anti-Scavenger Receptor Class B Type I (SR-BI) Monoclonal Antibody Therapy in Humanized Mice After Challenge With HCV Variants With In Vitro Resistance to SR-BI-Targeting Agents
10.1002/hep.27196
Hepatitis C Virus Replication and Golgi Function in Brefeldin A-Resistant Hepatoma-Derived Cells
10.1371/journal.pone.0074491
Permissivity of Primary Human Hepatocytes and Different Hepatoma Cell Lines to Cell Culture Adapted Hepatitis C Virus
10.1371/journal.pone.0070809
The Antimalarial Ferroquine Is An Inhibitor of Hepatitis C Virus
10.1002/hep.26273
Utilization of human DC-SIGN and L-SIGN for entry and infection of host cells by the New World arenavirus, Junin virus
10.1016/j.bbrc.2013.10.106
(-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry
10.1002/hep.24803
Mechanisms of Coronavirus Cell Entry Mediated by the Viral Spike Protein
10.3390/v4061011
Role of low-density lipoprotein receptor in the hepatitis C virus life cycle
10.1002/hep.25501
Endospanins Regulate a Postinternalization Step of the Leptin Receptor Endocytic Pathway
10.1074/jbc.M111.224857
Griffithsin Has Antiviral Activity against Hepatitis C Virus
10.1128/AAC.00633-11
Hepatitis C virus entry into the hepatocyte
10.2478/s11535-011-0076-y
Elastase-mediated Activation of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein at Discrete Sites within the S2 Domain
10.1074/jbc.M110.103275
Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites
10.1073/pnas.0809524106
Characterization of a Highly Conserved Domain within the Severe Acute Respiratory Syndrome Coronavirus Spike Protein S2 Domain with Characteristics of a Viral Fusion Peptide
10.1128/JVI.00079-09
SARS-coronavirus spike S2 domain flanked by cysteine residues C822 and C833 is important for activation of membrane fusion
10.1016/j.virol.2009.07.038
Molecular architecture of the bipartite fusion loops of vesicular stomatitis virus glycoprotein G, a class III viral fusion protein
10.1074/jbc.M708955200
Silencing of OB-RGRP in mouse hypothalamic arcuate nucleus increases leptin receptor signaling and prevents diet-induced obesity
10.1073/pnas.0706671104
Low levels of expression of leptin receptor at the cell surface result from constitutive endocytosis and intracellular retention in the biosynthetic pathway.
10.1074/jbc.m400508200
Regulation of hepatitis C virus polyprotein processing by signal peptidase involves structural determinants at the p7 sequence junctions.
10.1074/jbc.m406315200
Bovine viral diarrhea virus entry is dependent on clathrin-mediated endocytosis.
10.1128/jvi.79.16.10826-10829.2005
Ubiquitylation of leptin receptor OB-Ra regulates its clathrin-mediated endocytosis.
10.1038/sj.emboj.7600989
Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus.
10.1128/jvi.80.6.2832-2841.2006
Entry and release of hepatitis C virus in polarized human hepatocytes.
10.1128/JVI.00478-17
Secretion of Hepatitis C Virus Replication Intermediates Reduces Activation of Toll-Like Receptor 3 in Hepatocytes
10.1053/j.gastro.2018.03.020
The C-terminal domain of the MERS coronavirus M protein contains a trans-Golgi network localization signal
10.1074/jbc.RA119.008964
Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers
10.1101/2020.05.12.20098236
Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology
10.1101/2021.06.30.450483
Secretory Vesicles Are the Principal Means of SARS-CoV-2 Egress.
10.3390/cells10082047
Overcoming Culture Restriction for SARS-CoV-2 in Human Cells Facilitates the Screening of Compounds Inhibiting Viral Replication.
10.1128/aac.00097-21
Yves Rouillé
Rouillé Yves
ORCID: 0000-0003-0788-9271
Identification of class II ADP-ribosylation factors as cellular factors required for hepatitis C virus replication
10.1111/cmi.12572
Role of the prohormone convertase PC2 in the processing of proglucagon to glucagon
10.1016/s0014-5793(97)00892-2
Role of the prohormone convertase PC3 in the processing of proglucagon to glucagon-like peptide 1
10.1074/jbc.272.52.32810
Internal cleavage of the inhibitory 7B2 carboxyl-terminal peptide by PC2: A potential mechanism for its inactivation
10.1073/pnas.93.10.4919
DISTINCT HYDRO-OSMOTIC RECEPTORS FOR THE NEUROHYPOPHYSEAL PEPTIDES VASOTOCIN AND HYDRINS IN THE FROG RANA-ESCULENTA
10.1016/0143-4179(95)90039-x
HYPERPROINSULINAEMIA IN OBESE FAT/FAT MICE ASSOCIATED WITH A CARBOXYPEPTIDASE-E MUTATION WHICH REDUCES ENZYME-ACTIVITY
10.1038/ng0695-135
PROTEOLYTIC PROCESSING MECHANISMS IN THE BIOSYNTHESIS OF NEUROENDOCRINE PEPTIDES - THE SUBTILISIN-LIKE PROPROTEIN CONVERTASES
10.1006/frne.1995.1012
ACTION OF NEUROHYPOPHYSEAL GRANULE LYS-ARG ENDOPEPTIDASE ON SYNTHETIC POLYPEPTIDES COMPRISING THE PROCESSING SEQUENCE OF PROVASOPRESSIN-NEUROPHYSIN
10.1007/bf01200246
PROGLUCAGON IS PROCESSED TO GLUCAGON BY PROHORMONE CONVERTASE PC2 IN ALPHA-TC1-6 CELLS
10.1073/pnas.91.8.3242
SPECIAL EVOLUTION OF NEUROHYPOPHYSEAL HORMONES IN CARTILAGINOUS FISHES - ASVATOCIN AND PHASVATOCIN, 2 OXYTOCIN-LIKE PEPTIDES ISOLATED FROM THE SPOTTED DOGFISH (SCYLIORHINUS-CANICULUS)
10.1073/pnas.91.23.11266
A NEUROSECRETORY GRANULE LYS-ARG CA2+-DEPENDENT ENDOPEPTIDASE PUTATIVELY INVOLVED IN PROOXYTOCIN AND PROVASOPRESSIN PROCESSING
10.1016/0143-4179(92)90050-7
EVIDENCE FOR DISTINCT DIBASIC PROCESSING ENDOPEPTIDASES WITH LYS-ARG AND ARG-ARG SPECIFICITIES IN NEUROHYPOPHYSEAL SECRETORY GRANULES
10.1016/0006-291x(92)91618-z
PROCESSING ENDOPEPTIDASE DEFICIENCY IN NEUROHYPOPHYSEAL SECRETORY GRANULES OF THE DIABETES-INSIPIDUS (BRATTLEBORO) RAT
10.1007/bf01122032
HETEROLOGUE CONVERSION OF AMPHIBIAN HYDRIN-2 INTO VASOTOCIN THROUGH BOVINE GRANULE ALPHA-AMIDATING ENZYME
10.1111/j.1365-2826.1991.tb00233.x
NEUROHYPOPHYSEAL HORMONES AS MOLECULAR EVOLUTIONARY TRACERS - INVESTIGATIONS ON THE STURGEONS ACIPENSER-STELLATUS AND ACIPENSER-GULDENSTADTI
10.1016/0305-0491(91)90280-q
EVOLUTIONARY SPECIFICITY OF HYDRINS, NEW HYDROOSMOTIC NEUROPEPTIDES - OCCURRENCE OF HYDRIN-2 (VASOTOCINYL-GLY) IN THE TOAD BUFO-MARINUS BUT NOT IN THE VIPER VIPERA-ASPIS
10.1016/0014-5793(90)80783-f
IDENTIFICATION OF 2 TYPES OF NEUROPHYSINS IN XENOPUS-LAEVIS NEUROINTERMEDIATE PITUITARY HOMOLOGOUS TO MAMMALIAN MSEL-NEUROPHYSIN AND VLDV-NEUROPHYSIN
10.1016/0143-4179(90)90142-l
OCCURRENCE OF HYDRIN-2 (VASOTOCINYL-GLY), A NEW HYDROOSMOTIC NEUROHYPOPHYSEAL PEPTIDE, IN SECRETORY GRANULES ISOLATED FROM THE FROG (RANA-ESCULENTA) NEUROINTERMEDIATE PITUITARY
10.1159/000125343
HYDRINS, HYDROOSMOTIC NEUROHYPOPHYSEAL PEPTIDES - OSMOREGULATORY ADAPTATION IN AMPHIBIANS THROUGH VASOTOCIN PRECURSOR PROCESSING
10.1073/pnas.86.14.5272
ISOLATION OF NEUROSECRETORY GRANULES CONTAINING VASOTOCIN, MESOTOCIN, MSEL-NEUROPHYSINS AND VLDV-NEUROPHYSINS FROM GOOSE NEUROHYPOPHYSIS
10.1016/0143-4179(89)90090-5
PARTICULAR PROCESSING OF PRO-OPIOMELANOCORTIN IN XENOPUS-LAEVIS INTERMEDIATE PITUITARY - SEQUENCING OF ALPHA-MELANOCYTE-STIMULATING, AND BETA-MELANOCYTE-STIMULATING HORMONES
10.1016/0014-5793(89)80224-8
DUAL DUPLICATION OF NEUROHYPOPHYSEAL HORMONES IN AN AUSTRALIAN MARSUPIAL - MESOTOCIN, OXYTOCIN, LYSINE VASOPRESSIN AND ARGININE VASOPRESSIN IN A SINGLE GLAND OF THE NORTHERN BANDICOOT (ISOODON-MACROURUS)
10.1016/0006-291x(88)90691-2
ISOLATION OF NEUROSECRETORY GRANULES CONTAINING VASOPRESSIN AND MSEL-NEUROPHYSIN FROM GUINEA-PIG NEUROINTERMEDIATE PITUITARY
10.1016/0143-4179(88)90025-x
NEUROHYPOPHYSEAL HORMONES OF THE 1-MONTH-OLD BOVINE FETUS - ABSENCE OF VASOTOCIN DURING MAMMAL DEVELOPMENT
10.1016/0014-5793(88)80113-3
THE DISTRIBUTION OF LYSINE VASOPRESSIN (LYSIPRESSIN) IN PLACENTAL MAMMALS - A REINVESTIGATION OF THE HIPPOPOTAMIDAE (HIPPOPOTAMUS-AMPHIBIUS) AND TAYASSUIDAE (TAYASSU-ANGULATUS) FAMILIES
10.1016/0016-6480(88)90277-8
EVOLUTION OF MARSUPIALS TRACED BY THEIR NEUROHYPOPHYSEAL HORMONES - MICROIDENTIFICATION OF MESOTOCIN AND ARGININE VASOPRESSIN IN 2 AUSTRALIAN FAMILIES, DASYURIDAE AND PHASCOLARCTIDAE
10.1016/0016-6480(87)90195-x
GUINEA-PIG NEUROHYPOPHYSEAL HORMONES - PECULIAR PROCESSING OF THE 3-DOMAIN VASOPRESSIN PRECURSOR
10.1016/0014-5793(87)81294-2
Hexim1, a Novel Regulator of Leptin Function, Modulates Obesity and Glucose Disposal
10.1210/me.2015-1211
Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus
10.1128/jvi.00404-16
Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro
10.1007/s00705-016-2771-5
Morphology and Molecular Composition of Purified Bovine Viral Diarrhea Virus Envelope
10.1371/journal.ppat.1005476
Recent advances in human viruses imaging studies
10.1002/jobm.201500575
New Insights into the Understanding of Hepatitis C Virus Entry and Cell-to-Cell Transmission by Using the Ionophore Monensin A
10.1128/jvi.00192-15
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro
10.3389/fmicb.2015.00438
Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action
10.1128/jvi.01473-15
Regulation of core expression during the hepatitis C virus life cycle
10.1099/vir.0.070433-0
FTO contributes to hepatic metabolism regulation through regulation of leptin action and STAT3 signalling in liver
10.1186/1478-811x-12-4
Hepatitis C Virus Capsid Protein and Intracellular Lipids Interplay and Its Association With Hepatic Steatosis
10.5812/hepatmon.17812
Potent antiviral activity of Solanum rantonnetii and the isolated compounds against hepatitis C virus in vitro
10.1016/j.jff.2014.09.022
Structure-activity studies of (-)-epigallocatechin gallate derivatives as HCV entry inhibitors
10.1016/j.bmcl.2014.07.051
Hepatitis C Virus Replication and Golgi Function in Brefeldin A-Resistant Hepatoma-Derived Cells
10.1371/journal.pone.0074491
(-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry
10.1002/hep.24803
Hepatitis C Virus and Natural Compounds: A New Antiviral Approach?
10.3390/v4102197
Role of low-density lipoprotein receptor in the hepatitis C virus life cycle
10.1002/hep.25501
Endospanins Regulate a Postinternalization Step of the Leptin Receptor Endocytic Pathway
10.1074/jbc.M111.224857
HCV replication and assembly: a play in one act
10.2217/fvl.11.69
Hepatitis C Virus Assembly Imaging
10.3390/v3112238
Hepatocyte-derived cultured cells with unusual cytoplasmic keratin-rich spheroid bodies
10.1016/j.yexcr.2011.08.018
NS2 Protein of Hepatitis C Virus Interacts with Structural and Non-Structural Proteins towards Virus Assembly
10.1371/journal.ppat.1001278
Identification of a dominant endoplasmic reticulum-retention signal in yellow fever virus pre-membrane protein
10.1099/vir.0.015339-0
Identification of Basic Amino Acids at the N-Terminal End of the Core Protein That Are Crucial for Hepatitis C Virus Infectivity
10.1128/jvi.01393-10
Identification of GBF1 as a Cellular Factor Required for Hepatitis C Virus RNA Replication
10.1128/jvi.01190-09
LEPROT and LEPROTL1 cooperatively decrease hepatic growth hormone action in mice
10.1172/jci34997
Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins
10.1099/vir.0.82872-0
Silencing of OB-RGRP in mouse hypothalamic arcuate nucleus increases leptin receptor signaling and prevents diet-induced obesity
10.1073/pnas.0706671104
Hepatitis C virus entry depends on clathrin-mediated endocytosis
10.1128/jvi.00024-06
Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus
10.1128/jvi.80.6.2832-2841.2006
Ubiquitylation of leptin receptor OB-Ra regulates its clathrin-mediated endocytosis
10.1038/sj.emboj.7600989
Bovine viral diarrhea virus entry is dependent on clathrin-mediated endocytosis
10.1128/jvi.79.16.10826-10829.2005
Interactions between virus proteins and host cell membranes during the viral life cycle
10.1016/s0074-7696(05)45006-8
Significance of prohormone convertase 2, PC2, mediated initial cleavage at the proglucagon interdomain site, Lys70-Arg71, to generate glucagon
10.1210/en.2004-1118
Low levels of expression of leptin receptor at the cell surface result from constitutive endocytosis and intracellular retention in the biosynthetic pathway
10.1074/jbc.M400508200
The transmembrane domains of the prM and E proteins of yellow fever virus are endoplasmic reticulum localization signals
10.1128/jvi.78.22.12591-12602.2004
Visualization of TGN to endosome trafficking through fluorescently labeled MPR and AP-1 in living cells
10.1091/mbc.E02-06-0338
Dynamic processing of neuropeptides - Sequential conformation shaping of neurohypophysial preprohormones during intraneuronal secretory transport
10.1385/jmn:18:3:223
Yeast Vps55p, a functional homolog of human obesity receptor gene-related protein, is involved in late endosome to vacuole trafficking
10.1091/mbc.01-12-0597
Targeting of lysosomal proteins
10.1006/scdb.2000.0168
Unique evolution of neurohypophysial hormones in cartilaginous fishes: Possible implications for urea-based osmoregulation
10.1002/(sici)1097-010x(19991001)284:5<475::aid-jez2>3.0.co;2-9
Adaptive evolution of water homeostasis regulation in amphibians: Vasotocin and hydrins
10.1016/s0248-4900(97)83380-1
Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2
10.1073/pnas.94.13.6646
Molecular evolution of neurohypophysial hormones in relation to osmoregulation: the two fish options
10.1023/a:1007720909113
Identification of GBF1 as a cellular factor required for hepatitis E virus RNA replication
10.1111/cmi.12804
Entry and release of hepatitis C virus in polarized human hepatocytes.
10.1128/jvi.00478-17
An ecological approach to discover new bioactive extracts and products: the case of extremophile plants.
10.1111/jphp.12728
Endospanin1 affects oppositely body weight regulation and glucose homeostasis by differentially regulating central leptin signaling.
10.1016/j.molmet.2016.10.009
Identification of Novel Functions for Hepatitis C Virus Envelope Glycoprotein E1 in Virus Entry and Assembly.
10.1128/jvi.00048-17
Novel replicons and trans-encapsidation systems for Hepatitis C Virus proteins live imaging and virus-host interaction proteomics.
10.1016/j.jviromet.2017.04.009
Hepatitis C virus life cycle and lipid metabolism.
10.3390/biology3040892
Endospanin-2 enhances skeletal muscle energy metabolism and running endurance capacity
10.1172/jci.insight.98081
Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry
10.1128/jvi.01982-17
Investigation of the role of GBF1 in the replication of positive-sense single-stranded RNA viruses
10.1099/jgv.0.001099
Functional and Physical Interaction between the Arf Activator GBF1 and Hepatitis C Virus NS3 Protein
10.1128/JVI.01459-18
QuantIF: An ImageJ Macro to Automatically Determine the Percentage of Infected Cells after Immunofluorescence
10.3390/v11020165
Comparative Analysis of Hepatitis C Virus NS5A Dynamics and Localization in Assembly-Deficient Mutants
10.3390/pathogens10020172
Bidirectional genome-wide CRISPR screens reveal host factors regulating SARS-CoV-2, MERS-CoV and seasonal coronaviruses
10.1101/2021.05.19.444823
The C-terminal domain of the MERS coronavirus M protein contains a trans-Golgi network localization signal.
10.1074/jbc.ra119.008964
Ultrastructural modifications induced by SARS-CoV-2 in Vero cells: a kinetic analysis of viral factory formation, viral particle morphogenesis and virion release.
10.1007/s00018-020-03745-y
Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus, Is a New Inhibitor of Hepatitis C Virus RNA Replication.
10.1128/jvi.02009-18
Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture.
10.1371/journal.pone.0198226
Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology
10.1101/2021.06.30.450483
Secretory Vesicles Are the Principal Means of SARS-CoV-2 Egress
10.3390/cells10082047
Valentin Sencio
Sencio Valentin
ORCID: 0000-0002-6379-4317
Alteration of Flt3-Ligand-dependent de novo generation of conventional dendritic cells during influenza infection contributes to respiratory bacterial superinfection
10.1371/journal.ppat.1007360
Gut Dysbiosis during Influenza Contributes to Pulmonary Pneumococcal Superinfection through Altered Short-Chain Fatty Acid Production.
10.1016/j.celrep.2020.02.013
Interleukin-22 Immunotherapy during Severe Influenza Enhances Lung Tissue Integrity and Reduces Secondary Bacterial Systemic Invasion.
10.1128/IAI.00706-17
Bacterial immunogenic α-galactosylceramide identified in the murine large intestine: dependency on diet and inflammation.
10.1194/jlr.ra119000236
Toll-like receptor 5 agonist flagellin reduces influenza A virus replication independently of type I interferon and interleukin 22 and improves antiviral efficacy of oseltamivir.
10.1016/j.antiviral.2019.05.002
Short-chain fatty acids as a potential treatment for infections: a closer look at the lungs
10.1128/iai.00188-21
Influenza infection impairs the gut’s barrier properties and favors secondary enteric bacterial infection through reduced production of short-chain fatty acids
10.1128/iai.00734-20
The lung–gut axis during viral respiratory infections: the impact of gut dysbiosis on secondary disease outcomes
10.1038/s41385-020-00361-8
SARS-CoV-2 infection in nonhuman primates alters the composition and functional activity of the gut microbiota
10.1080/19490976.2021.1893113
Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology
10.1101/2021.06.30.450483
Karin Seron
Seron Karin
ORCID: 0000-0002-9667-133X
Identification of class II ADP-ribosylation factors as cellular factors required for hepatitis C virus replication
10.1111/cmi.12572
Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro
10.1007/s00705-016-2771-5
Characterization of Hepatitis C Virus Interaction with Heparan Sulfate Proteoglycans
10.1128/jvi.03647-14
Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro
10.1371/journal.pone.0142539
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro
10.3389/fmicb.2015.00438
Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action
10.1128/jvi.01473-15
Identification of Conserved Residues in Hepatitis C Virus Envelope Glycoprotein E2 That Modulate Virus Dependence on CD81 and SRB1 Entry Factors
10.1128/jvi.01402-14
Potent antiviral activity of Solanum rantonnetii and the isolated compounds against hepatitis C virus in vitro
10.1016/j.jff.2014.09.022
Structure-activity studies of (-)-epigallocatechin gallate derivatives as HCV entry inhibitors
10.1016/j.bmcl.2014.07.051
(-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry
10.1002/hep.24803
Hepatitis C Virus and Natural Compounds: A New Antiviral Approach?
10.3390/v4102197
Endospanins Regulate a Postinternalization Step of the Leptin Receptor Endocytic Pathway
10.1074/jbc.M111.224857
Identification of a dominant endoplasmic reticulum-retention signal in yellow fever virus pre-membrane protein
10.1099/vir.0.015339-0
Silencing of OB-RGRP in mouse hypothalamic arcuate nucleus increases leptin receptor signaling and prevents diet-induced obesity
10.1073/pnas.0706671104
ACDC/adiponectin polymorphisms are associated with severe childhood and adult obesity
10.2337/diabetes.55.02.06.db05-0971
Distinct impaired regulation of SOCS3 and long and short isoforms of the leptin receptor in visceral and subcutaneous fat of lean and obese women
10.1016/j.bbrc.2006.07.068
Genetic study of the CD36 gene In a French diabetic population
10.1016/s1262-3636(07)70143-x
GAD2 on chromosome 10p12 is a candidate gene for human obesity
10.1371/journal.pbio.0000068
Molecular cloning, functional complementation in Saccharomyces cerevisiae and enzymatic properties of phosphatidylinositol synthase from the protozoan parasite Toxoplasma gondii
10.1046/j.1432-1327.2000.01749.x
Disruption of six novel genes from the left arm of chromosome XV of Saccharomyces cerevisiae and basic phenotypic analysis of the generated mutants
10.1002/(sici)1097-0061(19990115)15:1<73::aid-yea341>3.0.co;2-q
Efficient transcription obtained by a new procedure of the tRNA-like structure of turnip yellow mosaic virus by a template-dependent and specific viral RNA polymerase
10.1016/s0166-0934(96)02166-0
Efficient transcription obtained by a new procedure of the tRNA-like structure of turnip yellow mosaic virus by a template-dependent and specific viral RNA polymerase (vol 64, pg 181, 1997)
10.1016/s0166-0934(96)02249-5
Expression of the 69K movement protein of turnip yellow mosaic virus in insect cells
10.1006/viro.1996.0246
Gene expression from viral RNA genomes
10.1007/bf00039391
Vascular movement of plant viruses
10.1094/mpmi-9-0435
IN-VITRO TRANSCRIPTS OF TURNIP YELLOW MOSAIC-VIRUS ENCOMPASSING A LONG 3' EXTENSION OR PRODUCED FROM A FULL-LENGTH CDNA CLONE HARBORING A 2 KB-LONG PCR-AMPLIFIED SEGMENT ARE INFECTIOUS
10.1016/s0923-2516(06)80049-x
Entry and release of hepatitis C virus in polarized human hepatocytes.
10.1128/jvi.00478-17
An ecological approach to discover new bioactive extracts and products: the case of extremophile plants.
10.1111/jphp.12728
Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus.
10.1128/jvi.00404-16
Middle East respiratory syndrome coronavirus infection is inhibited by griffithsin.
10.1016/j.antiviral.2016.07.011
Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus
10.1101/325126
Viral hepatitis in the Peruvian Amazon: Ethnomedical context and phytomedical resource.
10.1016/j.jep.2020.112735
Functional Carbon Quantum Dots as Medical Countermeasures to Human Coronavirus.
10.1021/acsami.9b15032
Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus, Is a New Inhibitor of Hepatitis C Virus RNA Replication.
10.1128/jvi.02009-18
Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture.
10.1371/journal.pone.0198226
Correction for Belouzard et al., "Entry and Release of Hepatitis C Virus in Polarized Human Hepatocytes".
10.1128/jvi.00309-18
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro.
10.3389/fmicb.2015.00488
A yeast t-SNARE involved in endocytosis.
10.1091/mbc.9.10.2873
Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology
10.1101/2021.06.30.450483
Nathalie deboosere
deboosere Nathalie
ORCID: 0000-0002-2873-5485
ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton.
10.15252/embr.201744371
Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling.
10.1016/j.celrep.2017.08.101
A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone.
10.3390/toxins9070227
Phenotypic assays for Mycobacterium tuberculosis infection.
10.1002/cyto.a.23129
Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays.
10.1021/acschembio.7b00091
STAT3 Represses Nitric Oxide Synthesis in Human Macrophages upon Mycobacterium tuberculosis Infection.
10.1038/srep29297
LppM impact on the colonization of macrophages by Mycobacterium tuberculosis.
10.1111/cmi.12619
A microscopic phenotypic assay for the quantification of intracellular mycobacteria adapted for high-throughput/high-content screening.
10.3791/51114
Adhesion of human pathogenic enteric viruses and surrogate viruses to inert and vegetal food surfaces.
10.1016/j.fm.2012.04.007
Viral elution and concentration method for detection of influenza A viruses in mud by real-time RT-PCR.
10.1016/j.jviromet.2011.10.013
Comparison of chlorine and peroxyacetic-based disinfectant to inactivate Feline calicivirus, Murine norovirus and Hepatitis A virus on lettuce.
10.1016/j.ijfoodmicro.2011.08.011
Direct detection of highly pathogenic avian influenza A/H5N1 virus from mud specimens.
10.1016/j.jviromet.2011.06.002
Development and validation of a concentration method for the detection of influenza a viruses from large volumes of surface water.
10.1128/aem.02484-10
A predictive microbiology approach for thermal inactivation of Hepatitis A virus in acidified berries.
10.1016/j.fm.2010.05.018
Assessment of the removal and inactivation of influenza viruses H5N1 and H1N1 by drinking water treatment.
10.1016/j.watres.2010.01.013
Intra-laboratory validation of a concentration method adapted for the enumeration of infectious F-specific RNA coliphage, enterovirus, and hepatitis A virus from inoculated leaves of salad vegetables.
10.1016/j.ijfoodmicro.2005.11.007
Modelling effect of physical and chemical parameters on heat inactivation kinetics of hepatitis A virus in a fruit model system.
10.1016/j.ijfoodmicro.2003.10.015
Host-pathogen systems for early drug discovery against tuberculosis.
10.1016/j.mib.2017.11.017
Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids.
10.1073/pnas.1707840114
Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis.
10.1038/s41598-017-11843-4
Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages.
10.1016/j.chom.2017.07.020
Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles.
10.1038/s41598-017-05453-3
Host-directed therapies offer novel opportunities for the fight against tuberculosis.
10.1016/j.drudis.2017.05.005
Cyclodextrin-based nanocarriers containing a synergic drug combination: A potential formulation for pulmonary administration of antitubercular drugs.
10.1016/j.ijpharm.2017.05.030
Impact of pe_pgrs33 Gene Polymorphisms on Mycobacterium tuberculosis Infection and Pathogenesis.
10.3389/fcimb.2017.00137
Clofazimine encapsulation in nanoporous silica particles for the oral treatment of antibiotic-resistant Mycobacterium tuberculosis infections.
10.2217/nnm-2016-0364
Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420.
10.1126/science.aag1006
How can nanoparticles contribute to antituberculosis therapy?
10.1016/j.drudis.2017.01.011
Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism.
10.1007/s00401-016-1652-z
Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria.
10.1111/mmi.13535
Mycobacterium tuberculosis LppM Displays an Original Structure and Domain Composition Linked to a Dual Localization.
10.1016/j.str.2016.07.009
Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro.
10.1007/s00705-016-2771-5
[Mycolactone: the amazing analgesic mycobacterial toxin].
10.1051/medsci/20163202007
A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters.
10.1039/c5ob02630j
Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action.
10.1128/jvi.01473-15
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro.
10.3389/fmicb.2015.00488
Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system.
10.1016/j.vaccine.2015.03.083
Cytosolic access of Mycobacterium tuberculosis: critical impact of phagosomal acidification control and demonstration of occurrence in vivo.
10.1371/journal.ppat.1004650
[High content screening in chemical biology: overview and main challenges].
10.1051/medsci/20153102016
Testing chemical and genetic Modulators in Mycobacterium tuberculosis infected cells using phenotypic assays.
10.1007/978-1-4939-2450-9_24
2-Carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1.
10.1021/cb5007163
High-content screening technology combined with a human granuloma model as a new approach to evaluate the activities of drugs against Mycobacterium tuberculosis.
10.1128/aac.03705-14
Mycobacterial toxin induces analgesia in buruli ulcer by targeting the angiotensin pathways.
10.1016/j.cell.2014.04.040
Ligand efficiency driven design of new inhibitors of Mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging, and linking approaches.
10.1021/jm500422b
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis.
10.1038/nm.3262
The balance of apoptotic and necrotic cell death in Mycobacterium tuberculosis infected macrophages is not dependent on bacterial virulence.
10.1371/journal.pone.0047573
Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis.
10.1021/jm300377g
Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitors.
10.1021/jm200825u
A novel specific edge effect correction method for RNA interference screenings.
10.1093/bioinformatics/btr648
Analogous mechanisms of resistance to benzothiazinones and dinitrobenzamides in Mycobacterium smegmatis.
10.1371/journal.pone.0026675
High-content screening in infectious diseases.
10.1016/j.cbpa.2011.05.023
Ethionamide boosters: synthesis, biological activity, and structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitors.
10.1021/jm200076a
Shortening the drug discovery pipeline: small molecule high content screening for lead discovery in neglected disease.
10.1186/1753-6561-5-s1-p38
High content phenotypic cell-based visual screen identifies Mycobacterium tuberculosis acyltrehalose-containing glycolipids involved in phagosome remodeling.
10.1371/journal.ppat.1001100
High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery.
10.4155/fmc.10.223
Functional characterization of the Mycobacterium tuberculosis serine/threonine kinase PknJ.
10.1099/mic.0.038133-0
High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors.
10.1371/journal.ppat.1000645
Systematic genetic nomenclature for type VII secretion systems.
10.1371/journal.ppat.1000507
Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting.
10.1016/j.biomaterials.2009.09.044
Automated HTS/HCS for antivirals using visual HIV full replication assays.
10.1186/1742-4690-6-s2-p82
Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis.
10.1126/science.1171583
Automated high-throughput siRNA transfection in raw 264.7 macrophages: a case study for optimization procedure.
10.1177/1087057108328762
Control of M. tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP.
10.1371/journal.ppat.0040033
ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity.
10.1128/jb.00469-07
[Aquatic insects and transmission of Mycobacterium ulcerans].
10.1051/medsci/20072367572
Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis.
10.1371/journal.ppat.0030062
Protection against Mycobacterium ulcerans lesion development by exposure to aquatic insect saliva.
10.1371/journal.pmed.0040064
Synthesis and antimycobacterial evaluation of benzofurobenzopyran analogues.
10.1016/j.bmc.2006.12.009
Inactivation of Rv2525c, a substrate of the twin arginine translocation (Tat) system of Mycobacterium tuberculosis, increases beta-lactam susceptibility and virulence.
10.1128/jb.00631-06
High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection.
10.1128/iai.02086-05
Benzofuro[3,2-f][1]benzopyrans: a new class of antitubercular agents.
10.1016/j.bmc.2006.03.033
An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis.
10.1128/iai.74.4.2128-2137.2006
Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence.
10.1128/iai.74.1.88-98.2006
Tuberculosis: from genome to vaccine.
10.1586/14760584.4.4.541
Functional analysis of early secreted antigenic target-6, the dominant T-cell antigen of Mycobacterium tuberculosis, reveals key residues involved in secretion, complex formation, virulence, and immunogenicity.
10.1074/jbc.m503515200
Immunogenic membrane-associated proteins of Mycobacterium tuberculosis revealed by proteomics.
10.1099/mic.0.27799-0
Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system.
10.4049/jimmunol.174.6.3570
Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis.
10.1016/j.tube.2004.09.009
ESAT-6 proteins: protective antigens and virulence factors?
10.1016/j.tim.2004.09.007
Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens.
10.1086/421468
Cell envelope protein PPE68 contributes to Mycobacterium tuberculosis RD1 immunogenicity independently of a 10-kilodalton culture filtrate protein and ESAT-6.
10.1128/iai.72.4.2170-2176.2004
Macro-array and bioinformatic analyses reveal mycobacterial 'core' genes, variation in the ESAT-6 gene family and new phylogenetic markers for the Mycobacterium tuberculosis complex.
10.1099/mic.0.26662-0
CD8+-T-cell responses of Mycobacterium-infected mice to a newly identified major histocompatibility complex class I-restricted epitope shared by proteins of the ESAT-6 family.
10.1128/iai.71.12.7173-7177.2003
Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis.
10.1038/nm859
Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti.
10.1046/j.1365-2958.2002.03237.x
Bacterial artificial chromosome-based comparative genomic analysis identifies Mycobacterium microti as a natural ESAT-6 deletion mutant.
10.1128/iai.70.10.5568-5578.2002
Disruption of HIV-1 integrase-DNA complexes by short 6-oxocytosine-containing oligonucleotides.
10.1021/bi015732y
IRG1 controls immunometabolic host response and restricts intracellular Mycobacterium tuberculosis infection
10.1101/761551
Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology
10.1101/2021.06.30.450483
